Review of radiofrequency microneedling: history, devices and uses.

Radiofrequency microneedling (RFM) has recently become a popular choice for the treatment of various dermatologic conditions and rejuvenation. Many studies have sought to evaluate the efficacy of RFM. However, its role in the management of these conditions remains unclear.

A Novel Germline Pathogenic Variant of Gene in an Iranian Pedigree with Familial Squamous Cell Carcinoma: A Brief Report.

Squamous cell carcinoma (SCC) is the most common human solid tumor and the leading cause of cancer death. SCC of the breast is a very rare type of cancer that has not been well researched. Early identification of the genetic factors involved can lead to early diagnosis and targeted treatment.

Synthesis, Characterization, Thermal Analysis, DFT, and Cytotoxicity of Palladium Complexes with Nitrogen-Donor Ligands.

Three new palladium complexes ([Pd(DABA)Cl], [Pd(CPDA)Cl], and [Pd(HZPY)Cl]) bearing dinitrogen ligands (DABA: 3,4-diaminobenzoic acid; CPDA: 4-chloro-o-phenylenediamine; HZPY: 2-hydraziniopyridine) were synthesized, characterized, and tested against breast cancer (MCF-7), prostate carcinoma cell line (PC3) and liver carcinoma cell line (HEPG2). [Pd(DABA)Cl] complex exhibited the highest inhibition percentage, lying between 68-71%. The hydrolysis mechanism of each palladium complex, the key step preceding the binding to the biological target, as well as their photophysical properties were explored by means of DFT and TDDFT computations.

Psoriasis and Co-morbidity.

Psoriasis is associated with multiple co-morbid medical conditions. The purpose of this study is to evaluate the relationships between psoriasis and cardiovascular disease, psoriatic arthritis, mental health conditions, and immune-mediated diseases, respectively. A literature search was performed during the study period January 1, 2015 to December 18, 2018.

Risk for appendicitis, cholecystitis, or diverticulitis in patients with psoriasis.

Numerous comorbidities have been associated with psoriasis; however, no studies have considered the relationship between psoriasis and appendicitis, cholecystitis, or diverticulitis. To determine the incidence rate and hazard risk (HR) ratio of appendicitis, cholecystitis, or diverticulitis in patients with psoriasis, we compared psoriasis patients with healthy controls from the Kaiser Permanente Southern California (KPSC) health network. The Cox proportional hazards regression model was used to examine the risk for appendicitis, cholecystitis, or diverticulitis.

Review of European registries for psoriasis.

Background: Patient registries are databases that contain clinical data for patients with a specific disease or medical condition.

Objective: The purpose was to identify psoriasis registries in Europe and examine their characteristics and implications.

Methods: We searched Google, the Registry of Patient Registries, and ClinicalTrials.

Dynamics and Spatial Genomics of the Nascent Transcriptome by Intron seqFISH.

Visualization of the transcriptome and the nuclear organization in situ has been challenging for single-cell analysis. Here, we demonstrate a multiplexed single-molecule in situ method, intron seqFISH, that allows imaging of 10,421 genes at their nascent transcription active sites in single cells, followed by mRNA and lncRNA seqFISH and immunofluorescence. This nascent transcriptome-profiling method can identify different cell types and states with mouse embryonic stem cells and fibroblasts.

Emerging therapies in psoriasis: a systematic review.

Many new biologics are being studied for use in psoriasis. In this review, we evaluate and summarize findings about emerging biologic therapies for psoriasis. We reviewed published data from phase 2 and 3 clinical trials of 2 IL-17 inhibitors (ixekizumab and brodalumab); 3 IL-23 inhibitors (guselkumab, tildrakizumab, and risankizumab); and 1 tumor necrosis factor (TNF) inhibitor (certolizumab pegol).

Do psoriasis patients engage in vigorous physical activity?

Psoriasis is associated with cardiovascular risk factors and myocardial infarction, but regular physical activity is known to decrease the risk of coronary heart disease. We performed a systematic review of PubMed articles indexed for MEDLINE as well as articles in the Embase database and Cochrane Library using the search terms and to determine the likelihood of psoriasis patients to engage in vigorous physical activity. A total of 353 nonduplicate articles were identified, and of 4 relevant studies, one provided sufficient data and was included in our review.

Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review.

Background: Although tuberculosis screening guidelines for psoriasis patients on TNF inhibitors exist, few studies have reported the prevalence of latent tuberculosis infection (LTBI) and conversion rates in this population.

Objective: To determine the incidence of LTBI and active tuberculosis in patients with psoriasis receiving TNF inhibitor therapy.

Methods: A total of 138 patients were included in our retrospective study of patients treated from September 2004 to September 2017.

Persisting Ulcerating Lesions After Cyclosporine Therapy for Erosions Found in Flexural Sites.

In February 2012, a patient with a 15-year history of painful, pruritic eruptions presented with a severe exacerbation that had lasted for the previous week. The patient also reported severe headaches, a fever of 38.9°C (102.

A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.

Purpose: Interleukin (IL)-17 and IL-23 inhibitors are the newest biologic agents used in the management of moderate-to-severe psoriasis. Active comparator studies allow for direct comparison of different biologic agents. We sought to systematically investigate the efficacy of newer biologic agents compared to earlier biologics.

Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?

An advanced understanding of the pathogenesis of psoriasis has led to the development of multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor inhibitors, ustekinumab, interleukin-17 inhibitors, and guselkumab (an interleukin-23 inhibitor recently approved for psoriasis) are commercially available biologic agents for psoriasis. Evidence from clinical trials provides pertinent information regarding the safety and efficacy of biologic agents for psoriasis, which should be integrated into clinical decision making.

Drug survival of biologic treatments in psoriasis: a systematic review.

Drug survival measures the length of time until discontinuation of a drug. The length of time a patient remains on a biologic drug is impacted by several factors such as tolerability, side effects, safety profile and effectiveness. To evaluate the long-term drug survival, data of the most commonly prescribed biologic medications used in the treatment of psoriasis, a systematic review was conducted.

Review of IL-17 inhibitors for psoriasis.

The development of biologic agents directed against distinct cytokines and receptors has advanced the therapeutic options available for psoriasis patients. Evidence from preclinical studies suggests that IL-17 may contribute to the pathogenesis of psoriasis. The objective was to review the safety and efficacy profile for each IL-17 inhibitor by evaluating phase III clinical trial data.